Stammdaten
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Unternehmen & Branche
| Name | AVADEL PHARMACEUTICALS PLC |
|---|---|
| Ticker | AVDL |
| CIK | 0001012477 |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 2,12 Mrd. USD |
| Beta | 1,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 77,467,000 | 20,000 | 0.00 | 199,448,000 | 98,225,000 |
| 2025-06-30 | 10-Q | 68,129,000 | 9,665,000 | 0.10 | 187,157,000 | 90,709,000 |
| 2025-03-31 | 10-Q | 52,511,000 | -4,920,000 | -0.05 | 167,949,000 | 74,070,000 |
| 2024-12-31 | 10-K | 169,117,000 | -48,832,000 | -0.51 | 164,236,000 | 73,848,000 |
| 2024-09-30 | 10-Q | 50,025,000 | -2,625,000 | -0.03 | 158,253,000 | 74,663,000 |
| 2024-06-30 | 10-Q | 41,504,000 | -13,822,000 | -0.14 | 157,521,000 | 70,288,000 |
| 2024-03-31 | 10-Q | 27,178,000 | -27,342,000 | -0.30 | 167,899,000 | 78,384,000 |
| 2023-12-31 | 10-K | 27,963,000 | -160,276,000 | -2.00 | 164,698,000 | 87,739,000 |
| 2023-09-30 | 10-Q | 7,014,000 | -36,274,000 | -0.41 | 203,100,000 | 110,149,000 |
| 2023-06-30 | 10-Q | 1,496,000 | -64,432,000 | -0.83 | 200,976,000 | 143,192,000 |
| 2023-03-31 | 10-Q | 0 | -30,784,000 | -0.48 | 140,739,000 | -38,166,000 |
| 2022-12-31 | 10-K | 0 | -137,464,000 | -2.29 | 132,785,000 | -21,145,000 |
| 2022-09-30 | 10-Q | 0 | -20,146,000 | -0.33 | 145,758,000 | -12,440,000 |
| 2022-06-30 | 10-Q | 0 | -63,444,000 | -1.07 | 157,938,000 | -3,332,000 |
| 2022-03-31 | 10-Q | -26,424,000 | -0.45 | 221,127,000 | 55,232,000 | |
| 2021-12-31 | 10-K | 0 | -77,329,000 | -1.32 | 247,265,000 | 78,244,000 |
| 2021-09-30 | 10-Q | 0 | -22,002,000 | -0.38 | 264,089,000 | 98,957,000 |
| 2021-06-30 | 10-Q | 0 | -19,581,000 | -0.33 | 282,591,000 | 118,880,000 |
| 2021-03-31 | 10-Q | 0 | -13,445,000 | -0.23 | 292,941,000 | 136,504,000 |
| 2020-12-31 | 10-K | 22,334,000 | 7,028,000 | 0.13 | 311,637,000 | 162,266,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | Weiss Asset Management LP | Open Market Sale | -11,112,052 | 21.00 | -233,353,092.00 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.